Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
TEL-AVIV, Israel and RALEIGH, N.C. , March 27, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D
TEL-AVIV, Israel and RALEIGH, N.C. , March 26, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting
Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential therapeutic applications in oncology and inflammatory digestive diseases TEL-AVIV , Israel and ...
View HTML
Toggle Summary RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update
Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018 Top-line results from the confirmatory Phase III study with TALICIA ®  for H. pylori infection expected in the second half of 2018 Net revenues of $2 million and gross profit of $1 . ...
View HTML
Toggle Summary RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma to Present at BIO CEO & Investor Conference
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, on Monday, February 12, 2018, at 10:45 am EST, at the New York Marriott Marquis Hotel, NY. ...
View HTML
Toggle Summary RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam® to Savings Program for Uninsured or Underinsured Patients
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA® for IBS-D
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
YELIVA ® , a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinoma Cholangiocarcinoma (bile duct cancer) is a highly lethal malignancy for which there is an urgent need for more effective treatments A Phase I clinical study with ...
View HTML